Engineered immune cells take on Hard-to-Treat cancers

NCT ID NCT03686124

Recruiting now Disease control Sponsor: Immatics US, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 29 times

Summary

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Some participants will also receive an immunotherapy drug called nivolumab. The goal is to find a safe dose and see if the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie
RECRUITING

Berlin, 12203, Germany
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States

Contact

Contact Email: •••••@•••••
Fred Hutchinson Cancer Center
ACTIVE_NOT_RECRUITING

Seattle, Washington, 98109, United States
Klinikum rechts der Isar der Technischen Universität München
RECRUITING

Munich, Bavaria, 81675, Germany
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

Contact Phone: •••-•••-••••
Memorial Sloan Kettering Cancer Center
ACTIVE_NOT_RECRUITING

New York, New York, 10065, United States
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run
RECRUITING

Columbus, Ohio, 43026, United States

Contact Email: •••••@•••••
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States

Contact Email: •••••@•••••
Thomas Jefferson University, Honickman Center
ACTIVE_NOT_RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Chicago Medical Center
ACTIVE_NOT_RECRUITING

Chicago, Illinois, 60637, United States
University of Colorado, Anschutz Medical Campus
ACTIVE_NOT_RECRUITING

Aurora, Colorado, 80045, United States
University of Miami Hospital and Clinics
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Pennsylvania, Perelamn Center for Advanced Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Email: •••••@•••••
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Universitätsklinikum Bonn - Medizinische Klinik III
RECRUITING

Bonn, North Rhine-Westphalia, 53127, Germany
Universitätsklinikum C.-G.-Carus Dresden
RECRUITING

Dresden, Saxony, 01307, Germany
Universitätsklinikum Hamburg-Eppendorf
RECRUITING

Hamburg, 20246, Germany
Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)
RECRUITING

Heidelberg, Baden-Wurttemberg, 69120, Germany
Universitätsklinikum Würzburg
RECRUITING

Würzburg, Bavaria, 97080, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
RECRUITING

Mainz, Rhineland-Palatinate, 55131, Germany

Conditions

Explore the condition pages connected to this study.

CANCER RECURRENT CANCER RECURRENT CANCER REFRACTORY CANCER SOLID TUMOR, ADULT